Compass Therapeutics, Inc. (CMPX)

Market Cap	401.76M
Revenue (ttm)	850,000
Net Income (ttm)	-47.76M
Shares Out	137.59M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,118,530
Open	3.100
Previous Close	3.080
Day's Range	2.850 - 3.200
52-Week Range	0.765 - 4.080
Beta	0.98
Analysts	Strong Buy
Price Target	12.50 (+328.08%)
Earnings Date	Mar 20, 2025

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 328.08% from the latest price.

Price Target

$12.5

(328.08% upside)

Analyst Consensus: Strong Buy